 Keep up to date with all of ClaremontBio's news
Join our RSS Feed
• February 14, 2013 - Claremont BioSolutions visits UCSD for the 34th Semiannual Biotechnology Calendar’s Vendor Showcase
On February 14, 2013 Claremont BioSolutions attended the 34th Semiannual Biotechnology Calendar’s Vendor Showcase held at UCSD in the Price Center Ballroom. The event featured the industry’s most cutting edge technologies for life sciences. ClaremontBio also unveiled its latest innovation, the Lateral Flow Reagent Dispenser to the UCSD community, alongside our current showcase of products for tissue homogenization, cell lysis, gDNA extraction, protein purification, and sample recovery.
If you would like to sign up for an event, please visit www.biotech-calendar.com. Interested in visiting us at our next event? Sign up for our mailing list to find out where we will be next! Also follow us on Twitter, Facebook, YouTube and Instagram!
• October 17, 2012 - Claremont BioSolutions Announces Strategic Investment and Technology Development Agreement with IQT.
Partnership with IQT will accelerate commercialization of
Prep-on-a-Chip technology Upland, CA – October 3, 2012 – Claremont BioSolutions, LLC, pioneer of micromotor-based rapid sample preparation devices, today announced a strategic partnership and technology development agreement with In‐Q‐Tel (IQT) to accelerate commercialization of its Prep-on-a-Chip sample preparation platform. IQT, based in Arlington, VA, is the independent strategic investment firm that identifies, adapts, and delivers, technologies that support the missions of the US intelligence community.
Claremont BioSolutions has harnessed the mechanical energy of micromotors used in the cell phone industry to create entirely disposable sample preparation devices that efficiently lyse any cell type, and simultaneously extract DNA or RNA. The battery-powered devices are currently hand-operated using a syringe or pipettor to transport the sample through a small chamber where cells are lysed, and nucleic acids are extracted in less than five minutes.
“The In-Q-Tel investment will aid us in our mission to multiplex and automate the handling of the devices, completing our development of the Prep-on-a-Chip™ platform” Gary Blackburn, CEO, said in a statement. “The technology is unique in that it can be readily integrated into disposable diagnostic cartridges, making POC and field-use of molecular diagnostics a realizable goal.”
“Claremont BioSolutions has taken an innovative approach to nucleic acid extraction,” said Syd Ulvick, Senior Vice President in charge of Physical and Biological Technologies at IQT, “We believe that further development of this technology will provide valuable capabilities for both the public and private sector.”
About Claremont BioSolutions.
Claremont BioSolutions (www.ClaremontBio.com) is a privately held, emerging growth technology company specializing in disposable devices that provide solutions to what is recognized as the “bottleneck” of DNA diagnostics – sample preparation. The company has developed proprietary devices which employ micromotors to perform very efficient mechanical cell lysis and DNA purification.
Contact:
Gary Blackburn, Ph.D.
Chief Executive Officer
Claremont BioSolutions, LLC
E-Mail: gblackburn@claremontbio.com
Phone: (626) 825-6962
Fax: (909) 946-1132
Address: 1182 Monte Vista, Ave., Suite 11
Upland, CA. 91786
##########
Source: Press Release
• July 16, 2012 - Claremont BioSolutions Awarded $3M Phase II SBIR NIH Grant
Claremont BioSolutions, LLC announced today that it has been awarded
a Phase II Small Business Innovation Research (SBIR) grant from the
NIH/NIAID. The $3M award, entitled “A fully integrated assay and
platform for detecting Clostridium difficile” will fund a collaborative
effort coordinated by ClaremontBio. Collaborators include Angelika
Niemz at the Keck Graduate Institute (http://www.kgi.edu) in Claremont, CA, David Boyle at Seattle-based PATH (http://www.path.org), and Ciaran Kelly at the Beth Israel Deaconess Medical Center.
“The NIH award will allow us to develop a small bench-top device to
detect Clostridium difficile both in patients and from potentially
contaminated surfaces in healthcare facilities. C. difficile is now the
most common hospital-acquired infection and has become a major cost
factor in hospitals and nursing homes,” commented ClaremontBio’s Chief
Technology Officer, Bruce Irvine. “The instrument which will be
developed under this award will allow rapid, near-patient diagnosis of
C. difficile, benefitting both the patient and the healthcare facility
by cutting the time to treatment and reducing the threat of facility
contamination.” He continued, “The same instrument will also help
facilities reduce costs by using it to monitor and then react
immediately to any contamination problems.”
ClaremontBio’s CEO, Dr. Gary Blackburn, commented that “we welcome
this ‘validation’ of our technologies following our successful
completion of the Phase I SBIR award last year. We have a new approach
to sample prep that will deliver diagnostic answers rapidly to
caregivers, researchers, and technicians in a wide range of environments
and industries.”
About Claremont BioSolutions.
Claremont BioSolutions (http://www.ClaremontBio.com)
is an emerging growth diagnostics company with unique solutions to the
“bottleneck” of sample preparation that is an essential first step to
any DNA or RNA diagnostic test. The company has pioneered efforts to
integrate sample preparation into sample-to-answer disposable cartridges
as the front-end to nearly any amplification and detection scheme
co-integrated into the same cartridge. ClaremontBio’s devices impart
mechanical energy directly to the fluid to lyse cells and extract DNA or
RNA and, for some application, fragment or shear the nucleic acid in a
controlled fashion. The sample prep process is complete in less than
five minutes and requires only a battery pack, no other instruments.
Contact Name: Bruce Irvine
Claremont BioSolutions, LLC
E-Mail: info(at)claremontbio(dot)com
Website: http://www.ClaremontBio.com
Phone: (877) 920-3887
Fax: (909) 946-1132
Address: 1182 Monte Vista, Ave., Suite #11
Upland, CA. 91786 See This Article on GenomeWeb PCR Insider
Source: Press Release
• December 14, 2011 - Claremont BioSolutions and Funakoshi Announce Distribution Agreement for Japan
Claremont BioSolutions, LLC (ClaremontBio) announced today that it has reached an
agreement with Funakoshi for the distribution of its products for sample
preparation, DNA isolation, and protein purification in Japan. The
agreement reflects ClaremontBio’s expansion of its marketing efforts
into Asia and Europe.
Read the Full Press Release
• December 5, 2011 - Claremont BioSolutions, LLC Reaches Distribution Agreement with Bioquote Limited
Claremont BioSolutions, LLC announced today that it has reached an
agreement with Bioquote Limited for the distribution of its products for
sample preparation, DNA isolation, and protein purification in the
United Kingdom and Ireland. The agreement extends ClaremontBio’s reach
into European markets and expands the customer base of their novel
products for sample preparation.
Read the Full Press Release
• July 13, 2011 - ClaremontBio Announces Official Release of HisExpress™ Columns
Claremont
BioSolutions, LLC (ClaremontBio) announced today the official release
of its HisExpress™ disposable columns for rapid His-tagged protein
purification in less than three minutes. The HisExpress™ column is one
of two products being officially released to the market in July that
focuses on the need for a quick and simple method of protein
purification. HisExpress™ columns feature easy and efficient protocols
for researchers in the life science and diagnostics fields.
Read the Full Press Release
• July 5, 2011 - Interview with ClaremontBio's Bruce Irvine
ClaremontBio's Chief Technology Officer, Bruce Irvine, had an opportunity to sit down with International Innovation,
a magazine dedicated to reporting the cutting edge of science and
technology from around the world. The magazine is featuring the
interview in its July 2011 editions. The interview highlights the
development of the development of the PureLyse® DNA Extraction Kit and the
unique technology that makes it ideal for inclusion in fully-integrated
meical diagnostics. The article also includes details about working
with C. diff and how point-of-care devices could reduce the bacteria's prevelance in hospitals and help reduce hospital-acquired infections.
Read the Full Interview
• June 20, 2011 - ClaremontBio announces release of MSDS sheets for safe Binding and Elution Buffers
ClaremontBio
is proud to offer sample prep devices that are safe, disposable, and
offer an insignificant impact on the environment. Many leading DNA
purification kits use harsh chemicals for the cell lysis and nucleic
acid extraction steps that require special disposal and safety measures.
All of ClaremontBio's PureLyse® DNA Extraction Kits, however, use only reagents that are completely safe to dispose down the drain and are non-toxic.
View the Binding Buffer MSDS
View the Elution Buffer MSDS
• June 6, 2011 - ClaremontBio is Proud to Announce its Use of Only Environmentally Friendly Products
Claremont
Biosolutions recognizes the importance of green technology and sustainable products that will help preserve the world for future generations. In accordance with this belief ClaremontBio is proud to announce its compliance with the Restriction of Hazardous Substances Directive (RoHS). This includes the use of only lead, mercury, and cadmium-free materials as well as other restrictions designed to improve the environment. Scientists at ClaremontBio strive to make buffers and reagents that are as environmentally friendly as possible. As a result all of ClarmontBio's extraction kits leave virtually zero footprint, are safely disposable, and require no harsh chemicals.
Learn more about RoHS
Learn more about sustainability
• May 30, 2011 - ClaremontBio Would Like to Congratulate Our Very Own Tanya Ferguson for the Publication of Her Article "Point-of-care nucleic acid testing for infectious diseases"
Nucleic acid testing (NAT) is quickly becoming an important technology for detecting infectious diseases, especially in point-of-care settings. Current NAT devices require PCR and are restricted to hospitals and large laboratories. However, with the emergence of new isothermal nucleic acid amplification methods it is possible to perform NAT in far more settings and with a turn around time of less than an hour. Detecting pathogens quickly is very important for preventing their spread and making sure correct treatments are prescribed as soon as possible. Development of nucleic acid testing will continue to be a crucial step in the continuing fight against deadly infectious diseases.
Click here to read Tanya's article
•
May 15, 2011 - ClaremontBio's next-generation sample prep devices featured in Genetic Engineering News.
ClaremontBio
is pleased to announce that the OmniLyse® Cell Lysis Kit, PureLyse® DNA
Extraction Kit, and His-Express™ Protein Purification Columns were all
highlighted in the most recent issue of Genetic Engineering News. The article notes the ease-of-use of all of
the devices and the fact that they can be used to lyse cells and extract DNA or
protein in under 10 minutes. The article also points out that ClaremontBio’s
new devices can handle a wide range of volumes and are ready made to be
incorporated as components in larger devices.
Click here to read the Full Article
• May 7, 2011 - ClaremontBio is Pleased to Announce the Publication of "Mechanical Disruption of Lysis-Resistan Bacteria using a Miniature, Low Power, Disposable Device" in the Journal of Clinical Microbiology
Cell lysis is an important component of the molecular detection of microorganisms because it allows nucleic acids and proteins within the cell to be released. Performing adequate lysis on gram-positive bacteria and other hard-to-lyse cells has been difficult, however, due to the thick cell-walls of these organisms. To investigate how these thick-walled organisms could be lyses the efficiency of ClaremontBio's OmniLyse® Cell Lysis Kit was compared to Biospec's Mini-beadbeaterTM as well as several combinations of beads and time intervals. This work was a joint effort between Claremont BioSolutions, the Keck Graduate Institute, and the Seattle Biomedical Research Institute.
Click here to read the full article
• April 5, 2011 - ClaremontBio Presents at 4th Annual Sample Prep Conference
Claremont Biosolutions
recently had the pleasure of attending the Knowledge Foundation's 4th Annual Sample Prep Conference held in San Diego, California. The Knowledge Foundation's Sample Prep Conference is an internationally recognized meeting for experts in sample preparation technologies for detection and identification of biological and chemical agents and threats. As an exhibitor ClaremontBio had the opportunity to present to government, industry, and academic experts from across the world.
See ClaremontBio's Presentation
See ClaremontBio's Poster
Visit the Knowledge Foundation
|
